Loading...
Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis
Non-Small Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) mutation benefit from a first line of treatment with tyrosine kinase inhibitors (TKIs). After progression, the choice of treatment is between chemotherapy and immune checkpoint inhibitors, but the role of EGFR m...
Na minha lista:
| Udgivet i: | Oncotarget |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Impact Journals LLC
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6349440/ https://ncbi.nlm.nih.gov/pubmed/30719215 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.26541 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|